Zentalis Pharmaceuticals (ZNTL)
(Real Time Quote from BATS)
$3.92 USD
-0.06 (-1.51%)
Updated Jul 12, 2024 01:36 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Zentalis Pharmaceuticals, Inc. (ZNTL) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.70 | $25.00 | $4.00 | 168.84% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Zentalis Pharmaceuticals, Inc. comes to $10.70. The forecasts range from a low of $4.00 to a high of $25.00. The average price target represents an increase of 168.84% from the last closing price of $3.98.
Analyst Price Targets (10)
Broker Rating
Zentalis Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 2.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on 10 recommendations.
Of the 11 recommendations deriving the current ABR, five are Strong Buy, representing 45.45% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ZNTL.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 0 | 0 | 0 |
ABR | 2.27 | 2.27 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | UBS | Eliana Merle | Not Available | Hold |
6/18/2024 | Wedbush Securities | Robert Driscoll | Hold | Strong Sell |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/18/2024 | Guggenheim Securities | Michael Schmidt | Strong Buy | Strong Buy |
6/18/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Hold |
6/18/2024 | Not Identified | Not Identified | Strong Buy | Hold |
5/8/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/7/2024 | SVB Securities | Andrew Berens | Hold | Hold |
4/1/2024 | Cowen & Co. | Tyler Van Buren | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.27 |
ABR (Last week) | 2.27 |
# of Recs in ABR | 11 |
Average Target Price | $10.70 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.83 |